{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:58:15Z","timestamp":1785002295452,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vaccine.2025.127180","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T23:27:36Z","timestamp":1746574056000},"page":"127180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis"],"prefix":"10.1016","volume":"56","author":[{"given":"Nikolaos","family":"Georgiadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Katsimpris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Tzanakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsiodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Beloukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Vassilakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros N.","family":"Sergentanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2025.127180_bb0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology of gonorrhea: a global perspective","volume":"16","author":"Kirkcaldy","year":"2019","journal-title":"Sex Health"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127180_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"Unemo","year":"2019","journal-title":"Gonorrhoea Nat Rev Dis Primer"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127180_bb0020","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World health organization global gonococcal antimicrobial surveillance program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"issue":"14","key":"10.1016\/j.vaccine.2025.127180_bb0025","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2013.08.067","article-title":"Vaccines against gonorrhea: current status and future challenges","volume":"32","author":"Jerse","year":"2014","journal-title":"Vaccine"},{"issue":"10102","key":"10.1016\/j.vaccine.2025.127180_bb0030","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127180_bb0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7774\/cevr.2019.8.2.110","article-title":"A meningococcal B vaccine induces cross-protection against gonorrhea","volume":"8","author":"Azze","year":"2019","journal-title":"Clin Exp Vaccine Res"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127180_bb0040","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3201\/eid2206.151093","article-title":"Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway","volume":"22","author":"Whelan","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127180_bb0045","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1473-3099(24)00236-6","article-title":"Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2\u00d72 factorial design","volume":"24","author":"Molina","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127180_bb0050","first-page":"95","article-title":"4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation","volume":"87","author":"Wang","year":"2023","journal-title":"J Inf Secur"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127180_bb0055","first-page":"247","article-title":"Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case-control study","volume":"50","author":"Raccagni","year":"2023","journal-title":"Sex Transm Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127180_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.31742","article-title":"Association of Group B Meningococcal Vaccine Receipt with Reduced Gonorrhea Incidence among University Students","volume":"6","author":"Robison","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127180_bb0065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","volume":"22","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2025.127180_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126312","article-title":"Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: a retrospective study","volume":"42","author":"Abara","year":"2024","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127180_bb0075","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","article-title":"Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California","volume":"76","author":"Bruxvoort","year":"2023","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.127180_bb0080","first-page":"A24","article-title":"OC-24 effectiveness of MenB vaccination against gonorrhoeae among PrEP users and PWH","volume":"100","author":"Labate","year":"2024","journal-title":"Sex Transm Infect"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.127180_bb0085","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1093\/ofid\/ofx180.002","article-title":"Possible impact of wide-scale vaccination against serogroup B Neisseria Meningitidis on gonorrhea incidence rates in one region of Quebec, Canada","volume":"4","author":"Longtin","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127180_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-023-00651-9","article-title":"OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans","volume":"8","author":"Viviani","year":"2023","journal-title":"Npj Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127180_bb0095","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV)","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"8775","key":"10.1016\/j.vaccine.2025.127180_bb0100","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"48","key":"10.1016\/j.vaccine.2025.127180_bb0105","doi-asserted-by":"crossref","first-page":"41767","DOI":"10.1074\/jbc.M111.289314","article-title":"Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the Main antigens of a novel vaccine against Neisseria meningitidis","volume":"286","author":"Esposito","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2025.127180_bb0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127180_bb0120","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127180_bb0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1600-0463.2012.02903.x","article-title":"Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae","volume":"120","author":"Hadad","year":"2012","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127180_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01668-19","article-title":"Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine","volume":"10","author":"Marjuki","year":"2019","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127180_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008602","article-title":"The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae","volume":"16","author":"Leduc","year":"2020","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127180_bb0140","first-page":"191","article-title":"Gonococcal MtrE and its surface-expressed loop 2 are immunogenic and elicit bactericidal antibodies","volume":"77","author":"Wang","year":"2018","journal-title":"J Inf Secur"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127180_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00388-3","article-title":"Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect","volume":"6","author":"Ruiz Garc\u00eda","year":"2021","journal-title":"Npj Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127180_bb0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3201\/eid2301.161205","article-title":"Frequent transmission of gonorrhea in men who have sex with men","volume":"23","author":"Fairley","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127180_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154047","article-title":"Evolutionary events associated with an outbreak of meningococcal disease in men who have sex with men","volume":"11","author":"Taha","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127180_bb0175","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1080\/21645515.2019.1627159","article-title":"Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults","volume":"15","author":"Martin\u00f3n-Torres","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127180_bb0180","article-title":"Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: a systematic review and meta-analysis","volume":"89","author":"Wang","year":"2024","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2025.127180_bb0185","first-page":"jiae383","article-title":"Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and Meta-analysis","author":"Abara","year":"2024","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127180_bb0195","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1186\/s12889-023-15516-y","article-title":"An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol","volume":"23","author":"Thng","year":"2023","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127180_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081675","article-title":"Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol","volume":"14","author":"Seib","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.127180_bb0205","author":"Study Details"},{"key":"10.1016\/j.vaccine.2025.127180_bb0210","author":"Study Details"},{"issue":"36","key":"10.1016\/j.vaccine.2025.127180_bb0215","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127180_bb0220","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz1241","article-title":"Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics","volume":"71","author":"Whittles","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2025.127180_bb0225","article-title":"Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection","author":"Nikitin","year":"2024","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127180_bb0230","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1128\/IAI.70.12.7063-7072.2002","article-title":"Comparative genomics identifies the Genetic Islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species","volume":"70","author":"Perrin","year":"2002","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25004773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25004773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T22:37:35Z","timestamp":1753483055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25004773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"alternative-id":["S0264410X25004773"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127180","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127180"}}